Danaher Corporation (DHR) vs Tarsus Pharmaceuticals, Inc. (TARS)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| DHR | TARS | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Diagnostics & Research | Biotechnology |
| Size band | LARGE | MID |
| Listing | NYSE | Nasdaq GS |
| Country | United States | United States |
| Theme | life-science-tools | vision-and-ophthalmology |
| Price and returns | ||
| Last close | $232.97 | $70.03 |
| Return · 1 week | +3.81% | +0.76% |
| Return · 1 month | +2.66% | −8.83% |
| Return · 3 months | +17.04% | +18.80% |
| Return · year to date | +1.33% | −13.30% |
| Return · 1 year | +5.78% | +2.74% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −4.05% | −23.49% |
| 52-week high | $242.80 | $91.53 |
| 52-week low | $160.93 | $53.89 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $163.77B | $3.19B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $834.36M | $46.68M |
| Employees | 58,000 | 370 |
| Valuation | ||
| Price to earnings · trailing | 39.18× | n/a (negative earnings) |
| Price to earnings · forward | 23.64× | n/a (negative forward earnings) |
| Price to sales | 6.15× | 5.26× |
| Price to book | 2.94× | 8.51× |
| Enterprise value to EBITDA | 22.06× | n/a (negative EBITDA) |
| Enterprise value to revenue | 7.05× | 4.34× |
| PEG ratio | 1.29 | — |
| Earnings per share · trailing | 5.61 | -1.08 |
| Profitability | ||
| Gross margin | 58.51% | 93.28% |
| Operating margin | 19.78% | −11.45% |
| Profit margin | 15.89% | −7.67% |
| Return on equity | 7.61% | −13.68% |
| Return on assets | 3.95% | −5.49% |
| Growth | ||
| Revenue growth | +5.50% | +69.40% |
| Earnings growth | +59.70% | — |
| Balance sheet and payout | ||
| Debt / equity (%) | 52.97 | 25.61 |
| Current ratio | 1.65 | 3.20 |
| Dividend yield | 0.74% | 0.00% |
| Payout ratio | 25.67% | — |
| Trend and volatility | ||
| RSI · 14 | 62.01 | 39.83 |
| ADX · 14 | 31.94 | 15.53 |
| 50-day average | $216.74 | $75.04 |
| 200-day average | $201.19 | $67.88 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 2.78% | 4.82% |
The full DHR analysis
Everything this table leaves out for Danaher Corporation: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the DHR argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full DHR analysisThe full TARS analysis
Everything this table leaves out for Tarsus Pharmaceuticals, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the TARS argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full TARS analysis